Latest Issue of Science News


News

Drug takes a shot at leukemia cells

From Orlando, Fla., at a meeting of the American Society of Hematology

A drug that targets solid tumors such as those of lung cancer might also fight blood cancers, a lab study shows.

Erlotinib (Tarceva) attacks cells by blocking a receptor protein that's abundant on the surface of some cancer cells (SN: 8/27/05, p. 139: Available to subscribers at Targeted Attack). Bone marrow cells—the blood-forming cells that go awry in patients with leukemia and other blood cancers—typically don't display this receptor.

Nevertheless, physician Simone Boehrer of the Gustave-Roussy Institute in Villejuif, France, and her colleagues tested erlotinib in a lab dish on bone marrow cells taken from 10 patients with either acute myeloid leukemia or a precancerous blood disorder called myelodysplastic syndrome.

Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.

X
This article is available only to subscribing members. Join SSP today or Log in.